A pharmacokinetic study of dalteparin (Fragmin®) during late pregnancy

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 4, 1998, Pages 343-350

  Blomback M ^a   Bremme, K ^a   Hellgren, M ^b   Lindberg, H ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c PFIZER INC   (United States)

Author keywords

Anti FXa; Low molecular mass heparin; Pharmacokinetics; Pregnancy; Thrombin markers

Indexed keywords

DALTEPARIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; FEMALE; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THIRD TRIMESTER PREGNANCY; THROMBOEMBOLISM; THROMBOGENESIS;

EID: 0031831989     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199806000-00006     Document Type: Article

References (28)

1. Department of Health and Social Security Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1991-1993. London: HMSO. 1996.
2. Franks AL, Atrash HK, Lawson HW, Colberg KS. Obstetrical pulmonary embolism mortality. United States 1970-85. Am J Public Health 1990; 80: 720-722.
3. Högberg U. Maternal mortality in Sweden. Thesis, Umeå, Sweden. 1985.
4. Mätzch T, Bergqvist D, Bergqvist A, Hodson S, Dawes J, Hedner U, et al. No transplacental passage of standard heparin or an enzymatically depolymerized low molecular weight heparin. Blood Coag Fibrinol 1991; 2: 73-78.
5. Forestier F, Daffas E, Capella-Pavlosky M. Low-molecular-weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34: 557-560.
6. Hellgren M. Treatment of and prophylaxis of thromboembolic complications during pregnancy and puerperium. Workshop. National Board of Health and Welfare. Drug Inform Committee, Sweden, 1995; 3: 179-198.
7. Turpie A. Management of deep venous thrombosis: Prevention and treatment. Pharmacol Ther, June, 1995; 7-15.
8. Wahlberg TB, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. Haemostasis 1994; 24: 55-56.
9. Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Low-molecular weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87: 380-383.
10. Hunt BJ, Doughty H-A, Majumdar G, Copplestone A, Kerslake S, Buchanan N, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.
11. Nelson-Piercy C, Letsky EA, de Swiet M. Lowmolecular-weight heparin for obstetric thromboprophylaxis - Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176: 1062-1068.
12. Krulder JWM, van den Besselaar AMHP, van der Meer FJM, Meinders AE, Briet E. Diurnal changes in heparin effect during continuous constant-rate infusion. A study in nine patients with venous thromboembolism. J Int Med 1994; 235: 411-417.
13. Andreotti F, Davies GJ, Hackett DR, Khan MI, de Bart ACW, Aber VR, et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol 1988; 62: 635-637.
14. Kapiotis S, Jilma B, Quehenberger P, Ruzicka K, Handler S, Speiser W. Morning hypercoagulability and hypofibrinolysis. Circulation 1997; 96: 19-21.
15. Bremme K, Lind H, Blombäck M. The effect of prophylactic heparin treatment of enhanced thrombin generation in pregnancy. Obstet Gynecol 1993; 81: 78-83.
16. Bremme K, Blombäck M. Monitoring of a woman with protein C deficiency during pregnancy and the effects of heparin. Thromb Haemorr Disorders 1992; 5: 11-15.
17. Blombäck M, Bremme K, Hellgren M, Seigbahn A, Lindberg H. Thromboprophylaxis with low molecular mass heparin, Fragmin (dalteparin), during pregnancy - a longitudinal safety study. Blood Coag Fibrinol 1998; 9: 1-9.
18. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
19. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416.
20. Abildgaard U, Lie M, Odegaard OR. Antithrombin (heparin co-factor) assay with new chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553.
21. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker Inc 1982: 409-417.
22. Bremme K, Östlund E, Almqvist I, Heinonen K, Blombäck M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and puerperium. Obstet Gynecol 1992; 80: 132-137.
23. Comeglio P, Fedi S, Alessandrello Liotta A, Cellai AP, Chiarantini E, Prisco D, et al. Blood clotting activation during normal pregnancy. Thromb Res 1996; 84: 199-202.
24. Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study of three low molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73: 398-401.
25. Hellgren M, Hägnevik K, Blombäck M. Heparin aerosol-effect on blood coagulation and pulmonary function. Thromb Res 1981; 21: 493-502.
26. Hiebert LM, Jaques LB. Heparin uptake on endothelium. Artery 1981; 2: 26-37.
27. Bratt G, Törnebohm E, Widlund L, Lockner D. A low molecular weight heparin fragment (Kabi 2165 Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-620.
28. Hellgren M, Nygårds EB. Longterm therapy with subcutaneous heparin during pregnancy. Gynecol Obstet Invest 1982; 13: 76-89.